New Delhi- An expert panel of India’s drugs regulator has recommended emergency use approval for Russia’s Sputnik V coronavirus vaccine, two sources said on Monday, which could make it the nation’s third to be approved as infections surge again.
India overtook Brazil to become the nation with the second-highest number of infections worldwide after the United States, as it battles a massive second wave, having given about 105 million doses among a population of 1.4 billion.
The panel of the Central Drugs Standard Control Organisation (CDSCO) recommended the authorization, said two people familiar with the matter, who sought anonymity as they were not authorized to speak to media.
Most panel recommendations are generally accepted by the regulator’s chief.
Neither Dr Reddy’s Laboratories, which markets the vaccine in India, nor the drugs regulator, responded immediately to Reuters’ requests for comment.
India is now using two vaccines, one developed by AstraZeneca and Oxford University, and the other by domestic firm Bharat Biotech.
Shares of Dr Reddy’s ended up 5% after the Economic Times newspaper reported the news.
The firm has helped run a small domestic trial to test the vaccine’s safety and ability to generate an immune response.
Sputnik V, developed by Moscow’s Gamaleya Institute, has proved 91.6% effective against Covid-19 and has been approved for use in more than 50 countries.
The Russian Direct Investment Fund has signed deals to produce more than 750 million doses of Sputnik V in India with six domestic firms.
Follow this link to join our WhatsApp group: Join Now
Be Part of Quality Journalism |
Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast. |
| ACT NOW |
| MONTHLY | Rs 100 |  |
| YEARLY | Rs 1000 | |
| LIFETIME | Rs 10000 | |
